Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.
about
Impact of New Genomic Technologies on Understanding Adverse Drug ReactionsPrecision medicine: from pharmacogenomics to pharmacoproteomicsSupporting precision medicine by data mining across multi-disciplines: an integrative approach for generating comprehensive linkages between single nucleotide variants (SNVs) and drug-binding sites.Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder.Pharmacometabolomics informs Pharmacogenomics.Identifying genetic loci affecting antidepressant drug response in depression using drug-gene interaction models.TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomicsImpact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.Personalized medicine: Genetic risk prediction of drug response.Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder.Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics.Lack of relationship between plasma levels of escitalopram and QTc-interval length.Utilization of Liver Microsomes to Estimate Hepatic Intrinsic Clearance of Monoamine Oxidase Substrate Drugs in Humans.
P2860
Q26787099-C3A4B5D8-18D2-4939-8564-41942BF06296Q28076871-07E2A573-DA0F-4FBB-8BB0-C3949BAEBB39Q31159438-4D280007-BF5A-4AB5-BEA6-7D5D2DCF803FQ36113601-D449907C-43F5-4F57-BB25-2EE5467427BFQ37158262-12657AB1-0945-41B7-B269-C92D4C971771Q37200660-EE29C014-AB88-432F-9A0B-6B93EB806BBAQ37213132-9D4789BD-363D-4395-8551-F9D17AAE593FQ38634986-DD4D221B-6C36-4373-B740-D89FBF47DCAEQ38756015-0923C0DC-B1C3-4627-BC55-8DFBE05B30BBQ38983579-A0DC1F83-74DC-40F9-A85F-94F9257E541CQ40569531-5A58601A-766D-49F4-B731-CDCF4FEDE9F8Q47659995-5034B931-0F3F-459E-B422-EB772B7C21FEQ47819968-868FF915-59DE-4C8A-9138-52960FF9DB66Q51080164-1C4B76F9-45C5-46A3-A4B3-857FF5B00242
P2860
Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Citalopram and escitalopram pl ...... ons: genome-wide associations.
@ast
Citalopram and escitalopram pl ...... ons: genome-wide associations.
@en
Citalopram and escitalopram pl ...... ons: genome-wide associations.
@nl
type
label
Citalopram and escitalopram pl ...... ons: genome-wide associations.
@ast
Citalopram and escitalopram pl ...... ons: genome-wide associations.
@en
Citalopram and escitalopram pl ...... ons: genome-wide associations.
@nl
prefLabel
Citalopram and escitalopram pl ...... ons: genome-wide associations.
@ast
Citalopram and escitalopram pl ...... ons: genome-wide associations.
@en
Citalopram and escitalopram pl ...... ons: genome-wide associations.
@nl
P2093
P2860
P50
P356
P1476
Citalopram and escitalopram pl ...... ons: genome-wide associations.
@en
P2093
Anthony J Batzler
Daniel Hall-Flavin
Daniel J Schaid
David A Mrazek
Evan Ogburn
Karen Snyder
Michiaki Kubo
Naoyuki Kamatani
Taisei Mushiroda
P2860
P304
P356
10.1111/BCP.12348
P407
P577
2014-08-01T00:00:00Z